{"disease":{"id":"crohn-colitis","name":"crohn colitis"},"drugs":{"marketed":[{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and Crohn's disease and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe ankylosing spondylitis and Crohn's disease and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis and Crohn's disease and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and Crohn's disease and rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe ankylosing spondylitis and Crohn's disease and rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis and ankylosing spondylitis and Crohn's disease and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis and ankylosing spondylitis and Crohn's disease and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis and rheumatoid arthritis and Crohn's disease and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, rheumatoid arthritis, Crohn's disease, and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, Crohn's disease, ulcerative colitis, and rheumatoid arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and rheumatoid arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, hidradenitis suppurativa, and atopic dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, hidradenitis suppurativa, atopic dermatitis, and plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":24,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03944447","title":"Outcomes Mandate National Integration With Cannabis as Medicine","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"OMNI Medical Services, LLC","has_results":false},{"nct_id":"NCT00622557","title":"General Surgical Outcomes Quality Improvement Database (UH-SOCRATES)","phase":"","overall_status":"COMPLETED","enrollment_count":200000,"lead_sponsor_name":"University Hospitals Cleveland Medical Center","has_results":false},{"nct_id":"NCT03456206","title":"Chronic Inflammatory Disease, Lifestyle and Risk of Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":57053,"lead_sponsor_name":"University of Southern Denmark","has_results":false},{"nct_id":"NCT04239521","title":"The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata","phase":"","overall_status":"COMPLETED","enrollment_count":51955,"lead_sponsor_name":"Momentum Data","has_results":false},{"nct_id":"NCT04985981","title":"The Prediction of Anastomotic Insufficiency Risk After Colorectal Surgery (PANIC) Study","phase":"","overall_status":"SUSPENDED","enrollment_count":11000,"lead_sponsor_name":"Michel Adamina, MD","has_results":false},{"nct_id":"NCT04806620","title":"Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Brain Inflammation Collaborative","has_results":false},{"nct_id":"NCT05257863","title":"Development of Machine Learning Models for the Prediction of Complications After Colonic, Colorectal and Small Intestine Anastomosis in Psychiatric and Non-psychiatric Patient Collectives (P-Study)","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Dr. Med Anas Taha","has_results":false},{"nct_id":"NCT00606346","title":"A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":4970,"lead_sponsor_name":"Janssen Biotech, Inc.","has_results":false},{"nct_id":"NCT07261826","title":"Real-World Study on Fecal Microbiota Transplantation: Long-Term Effectiveness and Safety Statistics","phase":"","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"Chen QiYi","has_results":false},{"nct_id":"NCT06583395","title":"Quest to Analyze One Thousand Humans Meditating","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3000,"lead_sponsor_name":"Tobias Moeller-Bertram","has_results":false},{"nct_id":"NCT03282903","title":"The PRognostic Effect of Environmental Factors in Crohn's and Colitis","phase":"","overall_status":"COMPLETED","enrollment_count":2629,"lead_sponsor_name":"University of Edinburgh","has_results":false},{"nct_id":"NCT04798625","title":"Vaccine Response to COVID-19 Vaccines in Patients Using Immunosuppressive Medication","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2300,"lead_sponsor_name":"Diakonhjemmet Hospital","has_results":false},{"nct_id":"NCT03662919","title":"One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":2274,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT07166588","title":"Research for the Precision Medicine in the Treatment of Inflammatory Bowel Disease","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":2000,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT04013152","title":"Clinical Database of Colorectal Robotic Surgery","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1800,"lead_sponsor_name":"Institut du Cancer de Montpellier - Val d'Aurelle","has_results":false},{"nct_id":"NCT06560021","title":"Utility of Random Biopsies in Patients With Inflammatory Bowel Disease","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1642,"lead_sponsor_name":"Abramson Cancer Center at Penn Medicine","has_results":false},{"nct_id":"NCT03571373","title":"PIBD-SETQuality: the Inception Cohort and Safety Registry","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"PIBD-Net","has_results":false},{"nct_id":"NCT02925338","title":"National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life","phase":"","overall_status":"COMPLETED","enrollment_count":1431,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06651281","title":"Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1380,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT01369355","title":"A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1282,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT05927064","title":"Study Evaluating the Persistence, Efficacy and Tolerability of Methotrexate in Inflammatory Bowel Disease Patients","phase":"","overall_status":"COMPLETED","enrollment_count":1282,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT04372108","title":"A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis","phase":"","overall_status":"RECRUITING","enrollment_count":1056,"lead_sponsor_name":"Janssen Scientific Affairs, LLC","has_results":false},{"nct_id":"NCT04188990","title":"Cost Effectiveness of an Intervention in Hospitalized Patients With Disease-related Malnutrition","phase":"NA","overall_status":"COMPLETED","enrollment_count":1051,"lead_sponsor_name":"Hospital Galdakao-Usansolo","has_results":false},{"nct_id":"NCT05190484","title":"bIosimilar of aDalimumab, an European evAluation","phase":"","overall_status":"UNKNOWN","enrollment_count":1050,"lead_sponsor_name":"Fresenius Kabi","has_results":false},{"nct_id":"NCT05542459","title":"Multi-omics to Predict Responses to Biologics in IBD","phase":"","overall_status":"UNKNOWN","enrollment_count":1050,"lead_sponsor_name":"Sixth Affiliated Hospital, Sun Yat-sen University","has_results":false},{"nct_id":"NCT03809728","title":"IDENTIFICATION OF PROGNOSTIC AND PREDICTIVE BIOMARKERS IN INFLAMMATORY BOWEL DISEASE","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT05578313","title":"Inflammatory Bowel Diseases (IBD) Cannabis Registry","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Eli Sprecher, MD","has_results":false},{"nct_id":"NCT04031469","title":"A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease","phase":"","overall_status":"SUSPENDED","enrollment_count":1000,"lead_sponsor_name":"ProgenaBiome","has_results":false},{"nct_id":"NCT04617184","title":"Registry and Biorepository for IBD in Central Texas","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University of Texas at Austin","has_results":false},{"nct_id":"NCT04912999","title":"Inflammatory Bowel Diseases Remission Registry","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Tel-Aviv Sourasky Medical Center","has_results":false},{"nct_id":"NCT04998084","title":"Advanced Therapy Registry of IBD Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Tel-Aviv Sourasky Medical Center","has_results":false},{"nct_id":"NCT06069167","title":"Bowel Urgency in Inflammatory Bowel Disease","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Paris IBD Center","has_results":false},{"nct_id":"NCT04089514","title":"A Real-world Study of Imraldi® Use","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT07263464","title":"The Association Between TNFSF4 Polymorphism and CD","phase":"","overall_status":"COMPLETED","enrollment_count":818,"lead_sponsor_name":"Second Affiliated Hospital of Wenzhou Medical University","has_results":false},{"nct_id":"NCT05051943","title":"A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response","phase":"","overall_status":"COMPLETED","enrollment_count":754,"lead_sponsor_name":"Fresenius Kabi","has_results":false},{"nct_id":"NCT04597905","title":"Paricipant Preferences in the Treatment of Inflammatory Bowel Disease (IBD) in Europe","phase":"","overall_status":"COMPLETED","enrollment_count":686,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT05458531","title":"Monitoring of Inflammatory Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":664,"lead_sponsor_name":"University of Nottingham","has_results":false},{"nct_id":"NCT03074656","title":"The Norwegian Drug Monitoring Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":611,"lead_sponsor_name":"Diakonhjemmet Hospital","has_results":false},{"nct_id":"NCT05598684","title":"SAPHIR : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Fresenius Kabi, France","has_results":false},{"nct_id":"NCT04060303","title":"ENhanced Recovery in CHildren Undergoing Surgery","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":599,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT04151420","title":"Real Life Remote Monitoring of Mild, Moderate and Severe Infectious Complications in IBD by Patient Reported Assessment","phase":"","overall_status":"COMPLETED","enrollment_count":584,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT03283085","title":"A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":557,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT02466217","title":"Phenomics in Autoimmune and Inflammatory Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":537,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04898530","title":"Diet Patterns in IBD in Central Texas","phase":"","overall_status":"SUSPENDED","enrollment_count":500,"lead_sponsor_name":"University of Texas at Austin","has_results":false},{"nct_id":"NCT05704413","title":"Digestive Biobank for Exploring Microbiota-host Interactions","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04663971","title":"Fertility and Pregnancy After Surgery IBD Audit","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"University of Campania Luigi Vanvitelli","has_results":false},{"nct_id":"NCT02326155","title":"To Evaluate the Safety and Efficacy of Remsima™ in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC)","phase":"","overall_status":"TERMINATED","enrollment_count":470,"lead_sponsor_name":"Celltrion","has_results":true},{"nct_id":"NCT04852666","title":"Comparative Effectiveness of Biologics or Small Molecule Therapies in Inflammatory Bowel Disease (IBD)","phase":"","overall_status":"COMPLETED","enrollment_count":465,"lead_sponsor_name":"University of North Carolina, Chapel Hill","has_results":true},{"nct_id":"NCT06338930","title":"Remote Monitoring of Patients With an Inflammatory Bowel Disease Under no or Maintenance Therapy","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":456,"lead_sponsor_name":"Universitaire Ziekenhuizen KU Leuven","has_results":false},{"nct_id":"NCT04014413","title":"Safety and Efficacy of Fecal Microbiota Transplantation","phase":"NA","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}